Navigation Links
CuraGen Corporation Regains NASDAQ Listing Compliance
Date:5/29/2008

BRANFORD, Conn., May 29 /PRNewswire-FirstCall/ -- CuraGen Corporation (Nasdaq: CRGN) today announced that it had received notification from The NASDAQ Stock Market that the Company has regained compliance with the requirements for continued listing on the NASDAQ Global Market, and that this matter is now closed.

In a letter dated January 28, 2008, NASDAQ had previously informed the Company that CuraGen had until July 28, 2008 to regain compliance with Marketplace Rule 4450(a)(5) by maintaining a closing bid price of $1.00 per share or higher for at least 10 consecutive business days.

"We are pleased with this decision by NASDAQ. Since receiving the initial communication from NASDAQ in late January, we have successfully advanced our lead clinical program CR011-vcMMAE into Phase II development, completed the sale of our interest in belinostat for approximately $38 million in cash thus far, removed $50.9 million in debt from our balance sheet, and announced a reduction in our burn rate guidance for the balance of the year. We believe these actions have generated value and contributed to the restoration of our full NASDAQ compliance, and we thank our shareholders who have shown confidence in CuraGen during this notification period," stated Dr. Timothy Shannon, President and Chief Executive Officer of CuraGen.

About CuraGen

CuraGen Corporation (Nasdaq: CRGN) is a clinical-stage biopharmaceutical company developing promising approaches for the treatment of cancer. CuraGen Corporation is headquartered in Branford, Connecticut. For additional information please visit http://www.curagen.com.

Forward-Looking Statements

Statements in this press release regarding management's future expectations, beliefs, intentions, goals, strategies, plans or prospects, including statements relating to CuraGen's successful advancement of its lead clinical program CR011-vcMMAE into Phase II development, the sale of CuraGen's ownership and development rights to belinostat, the removal of debt from CuraGen's balance sheet, the reduction in burn rate guidance for the balance of 2008 and the effect such actions have had on CuraGen's value and the compliance with NASDAQ's continued listing requirements may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by terminology such as "anticipate," "believe," "could," "could increase the likelihood," "estimate," "expect," "intend," "is planned," "may," "should," "will," "will enable," "would be expected," "look forward," "may provide," "would" or similar terms, variations of such terms or the negative of those terms. Such forward-looking statements involve known and unknown risks, uncertainties and other factors including the risk that any one or more of CuraGen's drug development programs will not proceed as planned for technical, scientific or commercial reasons or due to patient enrollment issues or based on new information from nonclinical or clinical studies or from other sources, the success of competing products and technologies, CuraGen's stage of development as a biopharmaceutical company, government regulation and healthcare reform, technological uncertainty and product development risks, product liability exposure, uncertainty of additional funding, CuraGen's history of incurring losses and the uncertainty of achieving profitability, reliance on research collaborations and strategic alliances, competition, patent infringement claims against CuraGen's products, processes and technologies, CuraGen's ability to protect its patents and proprietary rights and uncertainties relating to commercialization rights, as well as those risks, uncertainties and factors referred to in CuraGen's Quarterly Report on Form 10-Q for the period ended March 31, 2008 filed with the Securities and Exchange Commission under the section "Risk Factors," as well as other documents that may be filed by CuraGen from time to time with the Securities and Exchange Commission. As a result of such risks, uncertainties and factors, CuraGen's actual results may differ materially from any future results, performance or achievements discussed in or implied by the forward- looking statements contained herein. CuraGen is providing the information in this press release as of this date and assumes no obligations to update the information included in this press release or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Contacts:

Sean Cassidy

Vice President and Chief Financial Officer

scassidy@curagen.com

Glenn Schulman, Pharm.D.

Director Medical Communications

gschulman@curagen.com

(888) 436-6642

CRGN-F


'/>"/>
SOURCE CuraGen Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. CuraGen Sells 5 Million TopoTarget Shares for Approximately $12 Million
2. CuraGen Reports First Quarter 2008 Financial Results
3. CuraGen and TopoTarget Report Belinostat Results Presented at ASH and Provide Regulatory Update Following End-of-Phase II Meeting with FDA
4. CuraGen Reports Third Quarter 2007 Financial Results
5. CuraGen to Present at the Bear Stearns 20th Annual Healthcare Conference
6. Kewaunee Scientific Corporation Increases Quarterly Dividend
7. Alsius Corporation Awarded Three-Year Agreement With Premier, Inc.
8. Longs Drug Stores Corporation Announced at Its Annual Meeting of Stockholders
9. GenoLogics Releases BioVault Biospecimen Management Software in Partnership With GenVault Corporation
10. Linkwell Corporation Runs 24/7 Disinfectant Operations to Support Chinas Earthquake Relief Efforts
11. Seahorse Bioscience Enters into Agreement with Primetech Corporation to Bring XF Technology to Japanese Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... Tampa, FL (PRWEB) , ... March 30, 2017 , ... Grass pollen is the main ... sufferers allergic to the stuff. The season for grass pollen runs from May to July ... what’s a hay fever victim to do? HayMax™ allergen barrier balms ( http://www.haymax.us ) provide ...
(Date:3/29/2017)... ... March 30, 2017 , ... Youth Futures International (YFI) premiered its ... from high school and college students who have participated in the program every summer. ... YFI is now accepting applications for enrollment. Visit http://www.ghana.yfiexperience.org to learn ...
(Date:3/29/2017)... ... 30, 2017 , ... Sports Brand EXOUS Bodygear announced today a special sale ... for the remaining days of March, the price will be only $19.97. The EXOUS ... of just $10 (regular retail price $19.97). , The special promotional prices are to ...
(Date:3/29/2017)... , ... March 29, 2017 , ... ... Hours at a Walgreens store in Mississippi. AngioGenesis Labs, makers of HeartBoost, BrainBest ... in two southeastern states. Ingredients in HeartBoost, an over the counter heart healthy ...
(Date:3/29/2017)... Indianapolis, IN (PRWEB) , ... March 29, 2017 ... ... Benefits Study, this webinar provides insight into the challenges employers face in trying ... the complexity of managing employee benefits programs? Adding to the growing complexity, ...
Breaking Medicine News(10 mins):
(Date:3/29/2017)... March 29, 2017  Experts in the field ... devices like  Soberlink Systems  as a model for ... published in early 2017, concluded that remote blood ... managing patient recovery." The findings of ... Addiction Medicine, detail a range of variables that ...
(Date:3/29/2017)... Optometrists have staunchly strived to deliver ... in quality and care for more than a ... refraction technologies and process to challenge the eyeglass ... level of refraction and correction care standardization of ... Navy fighter pilots, but now available to every ...
(Date:3/29/2017)... 29, 2017 Transparency Market ... provides an exhaustive study of the U.S. substance abuse ... companies are functional in this market at present, ... leading companies, such as GlaxoSmithKline Plc., Pfizer Inc., ... on various marketing strategies to increase their visibility, ...
Breaking Medicine Technology: